Production of viral vaccines for veterinary use

被引:3
|
作者
van Gelder, Pieter [1 ]
Makoschey, Birgit [1 ]
机构
[1] Intervet Int Bv, MSD Anim Hlth, NL-5830 AA Boxmeer, Netherlands
来源
关键词
virus; vaccine; manufacturing; quality; RESPIRATORY SYNCYTIAL VIRUS; MOUTH-DISEASE VACCINES; EMULSION ADJUVANTS; ALUMINUM-HYDROXIDE; INFLUENZA-VIRUS; FEVER VIRUS; ANTIGEN; IMMUNOGENICITY; VACCINATION; ANTIBODIES;
D O I
10.2376/0005-9366-125-103
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
This review provides inside information on the production of vaccines for veterinary use, The vaccines against rinderpest as well as foot and mouth disease are considered milestones in the history of veterinary vaccine production. Modern vaccines are based on the scientific progress in virology, cell biology and immunology. While naturally occurring attenuated viruses or viruses obtained after passage in different animal species or cell culture were used as vaccine strains in the early vaccines, nowadays targeted mutagenesis can be applied to generate vaccine virus strains. In principle, the antigen production process is the same for live and inactivated vaccines. The vaccine virus is usually grown in cell culture, either in roller bottles or bioreactors. Most live vaccines are freeze-dried in order to enable storage in the refridgerator for a longer period. To this end, a so-called stabilizer is added to the culture medium. The inactivation of the vaccine virus for the production of killed vaccines is done by physical or chemical treatments that lead to denaturation of the proteins or damage of the nucleic acids. The inactivated antigen may be further purified and mixed with an adjuvant. The quality standards for vaccines are layed down in international regulations and laws. Numerous tests are performed during the different production steps and on the final product in order to warrant the quality of each batch.
引用
收藏
页码:103 / 109
页数:7
相关论文
共 50 条
  • [41] Veterinary Vaccines
    Woodland, David L.
    [J]. VIRAL IMMUNOLOGY, 2019, 32 (09) : 361 - 361
  • [42] Recommendations pertaining to the use of viral vaccines: Influenza
    不详
    [J]. SOUTH AFRICAN MEDICAL JOURNAL, 1996, 86 (02): : 193 - 193
  • [43] Use of animals in the development and control of viral vaccines
    Minor, PD
    [J]. REPLACEMENT, REDUCTION AND REFINEMENT OF ANIMAL EXPERIMENTS IN THE DEVELOPMENT AND CONTROL OF BIOLOGICAL PRODUCTS, 1996, 86 : 113 - 120
  • [44] USE OF ONCOLYTIC VIRAL VACCINES TO TREAT CANCER
    Lichty, Brian D.
    Wan, Yonghong
    Stojdl, David F.
    Bell, John C.
    Pol, Jonathan
    Stephenson, Kyle
    Atherton, Matthew
    Bridle, Byram
    [J]. ANTICANCER RESEARCH, 2014, 34 (10) : 6029 - 6030
  • [45] Viral vectors for use in the development of biodefense vaccines
    Lee, JS
    Hadjipanayis, AG
    Parker, MD
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (09) : 1293 - 1314
  • [46] Recommendations pertaining to the use of viral vaccines: Influenza
    不详
    [J]. SOUTH AFRICAN MEDICAL JOURNAL, 2001, 91 (02): : 129 - 129
  • [47] RETROSPECTIVE AND PROSPECTIVE VIEWS ON USE OF VIRAL VACCINES
    NORRBY, E
    [J]. ACTA MEDICA SCANDINAVICA, 1975, 197 (05): : 339 - 340
  • [48] PRESENT AND FUTURE USE OF VIRAL VACCINES IN ISRAEL
    SWARTZ, TA
    [J]. ISRAEL JOURNAL OF MEDICAL SCIENCES, 1983, 19 (11): : 1016 - 1020
  • [49] Regulatory Acceptance and Use of Serology for Inactivated Veterinary Rabies Vaccines
    Schiffelers, Marie-Jeanne W. A.
    Blaauboer, Bas J.
    Bakker, Wieger E.
    Hendriksen, Coenraad F. M.
    [J]. ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION, 2015, 32 (03) : 211 - 221
  • [50] CHARACTERIZATION OF AGGREGATED MICROCARRIER CULTURES FOR THE PRODUCTION OF VIRAL VACCINES
    SEIFERT, D
    RAM, K
    LEWIS, D
    PHILLIPS, J
    SHERIDAN, C
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1994, 207 : 18 - BIOT